• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Coherus Oncology Inc.

    11/13/25 5:23:26 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CHRS alert in real time by email
    S-8 1 tm2530759d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on November 13, 2025

    Registration No. 333-   

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Coherus Oncology, Inc.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware 27-3615821
    (State or other jurisdiction of
    incorporation or organization)
    (I.R.S. Employer
    Identification Number)

     

    333 Twin Dolphin Drive, Suite 600

    Redwood City, CA 94065

    (650) 649-3530 

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Coherus Oncology, Inc. 2014 Employee Stock Purchase Plan

    (Full Title of the Plan)

     

    Dennis M. Lanfear

    President and Chief Executive Officer

    Coherus Oncology, Inc.

    333 Twin Dolphin Drive, Suite 600

    Redwood City, CA 94065

    (650) 649-3530 

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Benjamin A. Potter, Esq.
    Drew Capurro, Esq.
    Latham & Watkins LLP
    140 Scott Drive
    Menlo Park, CA 94025
    (650) 328-4600
    Bryan McMichael
    Chief Financial Officer
    333 Twin Dolphin Drive, Suite 600
    Redwood City, CA 94065
    (650) 649-3530

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ¨ Accelerated filer x
    Non-accelerated filer ¨ Smaller reporting company x
        Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 1,500,000 shares of common stock of Coherus Oncology, Inc. (the “Registrant”), par value $0.0001 per share, reserved for issuance under the Registrant’s 2014 Employee Stock Purchase Plan (together with previous versions of such plan, and as may be further amended from time to time, the “2014 ESPP”), as approved by the Registrant’s stockholders on June 11, 2025 for which Registration Statements of the Registrant on Form S-8 (File Nos. 333-200593, 333-203356, 333-209936, 333-216679, 333-222700, 333-229480, 333-236068, 333-251876, and 333-262134) are effective.

     

    INCORPORATION BY REFERENCE OF CONTENTS OF

    REGISTRATION STATEMENTS ON FORM S-8

     

    Pursuant to Instruction E of Form S-8, the contents of the Registration Statements on Form S-8 filed with the Securities and Exchange Commission on November 25, 2014 (File No. 333-200593), April 10, 2015 (File No. 333-203356), March 4, 2016 (File No. 333-209936), March 14, 2017 (File No. 333-216679), January 25, 2018 (File No. 333-222700), February 1, 2019 (File No. 333-229480), January 24, 2020 (File No. 333-236068), January 4, 2021 (File No. 333-251876), and January 13, 2022 (File No. 333-262134) are incorporated by reference herein.

     

     

     

     

    EXHIBIT INDEX

     

            Incorporated by Reference    
    Exhibit
    Number
      Description   Form   Exhibit   Date Filed   Filed
    Herewith
                   
    3.1   Amended and Restated Certificate of Incorporation.   8-K   3.1   11/13/2014    
                         
    3.2   Certificate of Amendment to the Amended and Restated Certificate of Incorporation.   8-K   3.1   05/30/2025    
                         
    3.3   Second Amended and Restated Bylaws.   8-K   3.2   05/30/2025    
                   
    4.1   Form of Common Stock Certificate.   S-1/A   4.2   10/24/2014    
                   
    5.1   Opinion of Latham & Watkins LLP.               X
                   
    23.1   Consent of Latham & Watkins LLP (included in Exhibit 5.1).               X
                   
    23.2   Consent of Independent Registered Public Accounting Firm.               X
                   
    24.1   Power of Attorney (included in the signature page to this registration statement).               X
                   
    99.1(a)#   Coherus Oncology, Inc. 2014 Employee Stock Purchase Plan.   10-Q   10.3   08/07/2025    
                         
    99.1(b)#   Amendment No. 1 to Coherus Oncology, Inc. 2014 Employee Stock Purchase Plan.   10-Q   10.4   08/07/2025    
                   
    107   Filing Fee Table.               X

     

    #Indicates management contract or compensatory plan.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Redwood City, California, on November 13, 2025.

     

    COHERUS ONCOLOGY, INC.  
         
    By: /s/ Dennis M. Lanfear  
      Dennis M. Lanfear  
      President and Chief Executive Officer  

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Dennis M. Lanfear and Bryan McMichael, and each of them, with full power of substitution and full power to act without the other, his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file this Registration Statement, with all exhibits thereto, and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

     

    Signature   Title   Date
             
    /s/ Dennis M. Lanfear   Chairman, President and Chief Executive Officer   November 13, 2025
    Dennis M. Lanfear   (Principal Executive Officer)    
             
    /s/ Bryan McMichael   Chief Financial Officer   November 13, 2025
    Bryan McMichael   (Principal Financial Officer and Principal Accounting Officer)    
             
    /s/ Lee N. Newcomer   Director   November 13, 2025
    Lee N. Newcomer        
             
    /s/ Ali J. Satvat   Director   November 13, 2025
    Ali J. Satvat        
             
    /s/ Mats Wahlström   Director   November 13, 2025
    Mats Wahlström        
             
    /s/ Charles W. Newton   Director   November 13, 2025
    Charles W. Newton        
             
    /s/ Michael Ryan   Director   November 13, 2025
    Michael Ryan        
             
    /s/ Jill O’Donnell-Tormey   Director   November 13, 2025
    Jill O’Donnell-Tormey        
             
    /s/ Georgia Erbez   Director   November 13, 2025
    Georgia Erbez        
             
    /s/ Rita A. Karachun   Director   November 13, 2025
    Rita A. Karachun        

     

     

     

    Get the next $CHRS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CHRS

    DatePrice TargetRatingAnalyst
    9/4/2025Hold → Buy
    Maxim Group
    8/16/2024$4.00 → $1.50Buy → Neutral
    UBS
    11/17/2023$11.00Outperform
    Robert W. Baird
    11/8/2023Buy → Hold
    Maxim Group
    7/24/2023$12.00Buy
    Citigroup
    5/1/2023$24.00Buy
    Truist
    3/28/2023$11.00Neutral → Buy
    UBS
    6/14/2022$7.00Neutral
    UBS
    More analyst ratings

    $CHRS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director O'Donnell-Tormey Jill

    4 - Coherus Oncology, Inc. (0001512762) (Issuer)

    6/13/25 6:50:52 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Newcomer Lee Nisley

    4 - Coherus Oncology, Inc. (0001512762) (Issuer)

    6/13/25 6:50:17 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Wahlstrom Mats

    4 - Coherus Oncology, Inc. (0001512762) (Issuer)

    6/13/25 6:49:51 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CHRS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody

    – CHS-114 demonstrated robust and selective depletion of CCR8+ Tregs as well as favorable immune remodeling in tumor tissue from head and neck squamous cell carcinoma (HNSCC) patients – – CHS-114 administration resulted in selective depletion of CCR8+ Tregs and a >50% increase in intratumoral CD8 T cells – turning tumors "hot" REDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced new multiomic tumor and blood-based biomarker data from the dose expansion arm of its ongoing Phase 1b clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, as monotherapy and in combination with toripalimab in patients with recurre

    11/7/25 9:00:00 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

    – CHS-114, a highly selective Treg depleter, clinical program expanded to include colorectal cancer – – Q3 2025 ending cash, cash equivalents and marketable securities of $191.7 million – – LOQTORZI® net revenue was $11.2 million, a 12% increase over Q2 2025 – – Conference call today at 5:00 p.m. Eastern Standard Time – REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today reported financial results for the third quarter ended September 30, 2025 and provided an overview of recent business highlights. "In Q3 2025, we gained significant momentum on our strategy to develop innovative oncology therapies that substantially increase patient sur

    11/6/25 4:14:07 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

    – Responsible for Corporate Development, Investor Relations, Government Affairs – REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that Arvind Sood has joined the Company as Chief Strategy and Corporate Affairs Officer reporting to Denny Lanfear, Chairman and Chief Executive Officer. Mr. Sood's responsibilities include key externally facing and strategic functions. "We are thrilled to have a such a well-regarded senior biotechnology executive join us as we advance our innovative, next generation cancer therapeutics and drive LOQTORZI® revenues in nasopharyngeal carcinoma," said Denny Lanfear, Coherus Oncology Chairman and Chief

    11/6/25 1:54:45 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CHRS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Coherus BioSciences upgraded by Maxim Group

    Maxim Group upgraded Coherus BioSciences from Hold to Buy

    9/4/25 7:57:13 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coherus BioSciences downgraded by UBS with a new price target

    UBS downgraded Coherus BioSciences from Buy to Neutral and set a new price target of $1.50 from $4.00 previously

    8/16/24 7:33:26 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Robert W. Baird initiated coverage on Coherus BioSciences with a new price target

    Robert W. Baird initiated coverage of Coherus BioSciences with a rating of Outperform and set a new price target of $11.00

    11/17/23 7:37:50 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CHRS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for CIMERLI issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug CIMERLI (SUPPL-5) with active ingredient RANIBIZUMAB-EQRN has changed to 'Approval' on 05/21/2024. Application Category: BLA, Application Number: 761165, Application Classification:

    5/22/24 9:41:01 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for LOQTORZI issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug LOQTORZI (SUPPL-1) with active ingredient TORIPALIMAB-TPZI has changed to 'Approval' on 04/22/2024. Application Category: BLA, Application Number: 761240, Application Classification:

    4/23/24 4:41:07 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for UDENYCA issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug UDENYCA (SUPPL-15) with active ingredient PEGFILGRASTIM-CBQV has changed to 'Approval' on 12/22/2023. Application Category: BLA, Application Number: 761039, Application Classification:

    12/27/23 4:38:39 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CHRS
    SEC Filings

    View All

    SEC Form S-3 filed by Coherus Oncology Inc.

    S-3 - Coherus Oncology, Inc. (0001512762) (Filer)

    11/13/25 5:29:51 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by Coherus Oncology Inc.

    S-8 - Coherus Oncology, Inc. (0001512762) (Filer)

    11/13/25 5:23:26 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coherus Oncology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Coherus Oncology, Inc. (0001512762) (Filer)

    11/13/25 5:13:40 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CHRS
    Financials

    Live finance-specific insights

    View All

    Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update

    – CHS-114, a highly selective Treg depleter, clinical program expanded to include colorectal cancer – – Q3 2025 ending cash, cash equivalents and marketable securities of $191.7 million – – LOQTORZI® net revenue was $11.2 million, a 12% increase over Q2 2025 – – Conference call today at 5:00 p.m. Eastern Standard Time – REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today reported financial results for the third quarter ended September 30, 2025 and provided an overview of recent business highlights. "In Q3 2025, we gained significant momentum on our strategy to develop innovative oncology therapies that substantially increase patient sur

    11/6/25 4:14:07 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025

    REDWOOD CITY, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that its third quarter 2025 financial results will be released after market close on Thursday, November 6, 2025. Starting at 5:00 p.m. Eastern Time on November 6, 2025, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion of the live conference call. Conference Call Information When: Thursday, November 6, 2025, starting at 5:00 p.m. Eastern Standard Time To access the conference call, please pre-register thr

    10/30/25 8:30:00 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

    – LOQTORZI net revenue was $10.0 million, a 36% increase over Q1 2025 – – Data readouts for CHS-114 and casdozokitug on track for 1H 2026 – – Q2 2025 ending cash, cash equivalents and marketable securities of $238 million – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today reported financial results for the second quarter ended June 30, 2025 and provided an overview of recent business highlights. "Coherus Oncology is dedicated to significantly extending survival for people with cancer," said Denny Lanfear, Coherus Chairman and Chief Executive Officer. "We are execu

    8/7/25 4:41:26 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CHRS
    Leadership Updates

    Live Leadership Updates

    View All

    $CHRS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

    – Responsible for Corporate Development, Investor Relations, Government Affairs – REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ:CHRS), today announced that Arvind Sood has joined the Company as Chief Strategy and Corporate Affairs Officer reporting to Denny Lanfear, Chairman and Chief Executive Officer. Mr. Sood's responsibilities include key externally facing and strategic functions. "We are thrilled to have a such a well-regarded senior biotechnology executive join us as we advance our innovative, next generation cancer therapeutics and drive LOQTORZI® revenues in nasopharyngeal carcinoma," said Denny Lanfear, Coherus Oncology Chairman and Chief

    11/6/25 1:54:45 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors

    REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus or the Company, NASDAQ:CHRS) today announced that Rita Karachun, CPA, CGMA, most recently Senior Vice President (SVP) and Global Controller for Merck & Co., Inc., (Merck) was appointed to its Board of Directors effective May 31, 2024. Ms. Karachun has nearly four decades of experience leading finance, accounting, and SEC reporting functions at multi-billion-dollar global companies. Her experience includes more than 17 years at Merck, where she held positions of increasing financial management responsibility. As Global Controller at Merck, Ms. Karachun managed a global team responsible for all accou

    6/5/24 9:00:00 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors

     – Recognized biopharma commercialization and market access leader to support Coherus' strategic vision and multiple product launches – REDWOOD CITY, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company", NASDAQ:CHRS), today announced the appointment to its Board of Directors of biopharma commercialization and market access expert Michael Ryan, Pharm. D. Dr. Ryan has four decades of experience working in academia and the biopharmaceutical industry bringing high-value therapeutics to patients. Dr. Ryan's distinguished career includes most recently serving as Senior Vice President and Head for U.S. and Worldwide Value, Access, Pricing and Health Ec

    7/20/23 4:04:53 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Coherus BioSciences Inc.

    SC 13G - Coherus BioSciences, Inc. (0001512762) (Subject)

    11/13/24 4:30:25 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Coherus BioSciences Inc.

    SC 13G/A - Coherus BioSciences, Inc. (0001512762) (Subject)

    7/23/24 8:23:56 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Coherus BioSciences Inc. (Amendment)

    SC 13G/A - Coherus BioSciences, Inc. (0001512762) (Subject)

    5/22/24 7:27:00 PM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care